Roche's Perjeta regimen gets FDA priority review in breast cancer

ZURICH (Reuters) - The U.S. Food and Drug Administration (FDA) has granted priority review for Roche's Perjeta in combination with Herceptin and chemotherapy for treating HER2-positive early breast cancer after surgery, Roche said on Friday.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news